Bone marrow iron, iron indices, and the response to intravenous iron in patients with non-dialysis-dependent CKD
- PMID: 20079959
- DOI: 10.1053/j.ajkd.2009.10.043
Bone marrow iron, iron indices, and the response to intravenous iron in patients with non-dialysis-dependent CKD
Erratum in
- Am J Kidney Dis. 2010 Nov;5(11):2137-8
Abstract
Background: Information about iron stores and their relationship with transferrin saturation (TSAT), serum ferritin, and the erythropoietic response to iron therapy is scarce in anemic non-dialysis-dependent patients with chronic kidney disease (CKD). We examined the diagnostic utility of peripheral-iron indices and the erythropoietic response to intravenous iron as indices of iron store depletion using bone marrow iron as a reference test in anemic non-dialysis-dependent patients with CKD.
Study design: Diagnostic test study.
Setting & participants: 100 anemic (hemoglobin <11 g/dL) patients with CKD stages 3-5, not receiving epoetin and iron.
Index tests: TSAT index and serum ferritin level at baseline and increase in hemoglobin level 1 month after 200 mg of iron sucrose daily for 5 days.
Reference test: Bone marrow iron (assessed using aspiration and Perls' stain), depleted versus replete, at baseline.
Measurements: Area under the receiver operating characteristic curve (AUROC), sensitivity, and specificity of peripheral-iron indices and erythropoietic response to describe bone marrow iron stores.
Results: Bone marrow iron stores were depleted in 48% of patients at baseline. In iron-depleted versus -replete subjects, mean hemoglobin level, median TSAT index, median serum ferritin level, and hemoglobin level increase after iron sucrose administration were 8.74 +/- 1.1 (SD) versus 9.22 +/- 0.9 g/dL (P = 0.02), 19% (interquartile range [IQR], 15%) versus 28% (IQR, 12%; P < 0.001), 100 (IQR, 131) versus 220 ng/mL (IQR, 213; P < 0.001), and 1.2 +/- 0.4 versus 0.8 +/- 0.3 g/dL (P < 0.001), respectively. TSAT, ferritin level, and increase in hemoglobin level AUROCs were similar: 0.75 (95% CI, 0.66-0.85), 0.76 (95% CI, 0.66-0.85), and 0.74 (95% CI, 0.65-0.84), respectively.
Limitations: Bone marrow iron as the index of iron stores.
Conclusions: Half the anemic patients with CKD stages 3-5 had depleted iron stores. Peripheral-iron indices and erythropoietic response had equivalent, but limited, utility in identifying depletion of bone marrow iron stores. Use of these indices to indicate depletion of iron stores should be reconsidered.
Copyright 2010 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.
Comment in
-
Bone marrow iron in CKD: correlation with functional iron deficiency.Am J Kidney Dis. 2010 Apr;55(4):617-21. doi: 10.1053/j.ajkd.2009.12.027. Am J Kidney Dis. 2010. PMID: 20338462 No abstract available.
-
Notice of redundant publication: Am J Kidney Dis. 2010;55(4):639-647.Am J Kidney Dis. 2010 Nov;56(5):1016. doi: 10.1053/j.ajkd.2010.09.001. Am J Kidney Dis. 2010. PMID: 21038487 No abstract available.
-
Notice of redundant publication and correction.Clin J Am Soc Nephrol. 2010 Nov;5(11):2137-8. doi: 10.2215/cjn.201033333333. Clin J Am Soc Nephrol. 2010. PMID: 21105214 No abstract available.
Similar articles
-
Comparison of intravenous iron sucrose to oral iron in the treatment of anemic patients with chronic kidney disease not on dialysis.Nephron Clin Pract. 2005;100(3):c55-62. doi: 10.1159/000085049. Epub 2005 Apr 11. Nephron Clin Pract. 2005. PMID: 15824508 Clinical Trial.
-
Can the response to iron therapy be predicted in anemic nondialysis patients with chronic kidney disease?Clin J Am Soc Nephrol. 2010 Mar;5(3):409-16. doi: 10.2215/CJN.04280609. Epub 2009 Dec 17. Clin J Am Soc Nephrol. 2010. PMID: 20019121 Free PMC article.
-
A comprehensive vision for intravenous iron therapy.Am J Kidney Dis. 2008 Dec;52(6 Suppl):S14-20. doi: 10.1053/j.ajkd.2008.09.003. Am J Kidney Dis. 2008. PMID: 19010257
-
[Guidelines for the treatment of anemia in chronic renal failure].G Ital Nefrol. 2003 Sep-Oct;20 Suppl 24:S61-82. G Ital Nefrol. 2003. PMID: 14666504 Review. Italian.
-
Effect of recombinant human erythropoietin on iron balance in maintenance hemodialysis: theoretical considerations, clinical experience and consequences.Clin Nephrol. 1992;38 Suppl 1:S92-7. Clin Nephrol. 1992. PMID: 1295714 Review.
Cited by
-
Anemia in heart failure patients.ISRN Hematol. 2012;2012:246915. doi: 10.5402/2012/246915. Epub 2012 Mar 25. ISRN Hematol. 2012. PMID: 22536520 Free PMC article.
-
Serum Biomarkers of Iron Stores Are Associated with Increased Risk of All-Cause Mortality and Cardiovascular Events in Nondialysis CKD Patients, with or without Anemia.J Am Soc Nephrol. 2021 Aug;32(8):2020-2030. doi: 10.1681/ASN.2020101531. Epub 2021 Jul 8. J Am Soc Nephrol. 2021. PMID: 34244326 Free PMC article.
-
Renal anemia and hydration status in non-dialysis chronic kidney disease: Is there a link?J Med Life. 2018 Oct-Dec;11(4):293-298. doi: 10.25122/jml-2019-0002. J Med Life. 2018. PMID: 30894885 Free PMC article.
-
Anaemia: FIND-CKD: intravenous iron in predialysis CKD.Nat Rev Nephrol. 2014 Sep;10(9):488-9. doi: 10.1038/nrneph.2014.139. Epub 2014 Aug 5. Nat Rev Nephrol. 2014. PMID: 25092153 No abstract available.
-
Anemia Prevalence, Type, and Associated Risks in a Cohort of 5.0 Million Insured Patients in the United States by Level of Kidney Function.Am J Kidney Dis. 2023 Feb;81(2):201-209.e1. doi: 10.1053/j.ajkd.2022.07.014. Epub 2022 Sep 28. Am J Kidney Dis. 2023. PMID: 36181996 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical